RESUMO
BACKGROUND: The impact of sarcopenia in patients undergoing simultaneous liver and kidney transplantation (SLKT) has not been fully delineated. The aim of this single-centre-cohort-study was to evaluate the impact of sarcopenia on the clinical outcomes. METHODS: Between 2003 and 2018, 79 patients underwent SLKT. Sarcopenia was assessed via the total psoas muscle area (TPA) at the level of the 3rd. lumbar vertebra. Sarcopenia threshold was TPAâ¯<â¯1460â¯mm2 (women) and <1560â¯mm2 (men). We identified post-operative biliary, vascular and digestive complications. Survival analysis was performed by the Kaplan Meier method (log-rank test). RESULTS: We included 43/79 SLKT recipients (56%male, median age of 58 [53-63] years). The prevalence of cirrhosis was 74% (nâ¯=â¯32) with median MELD-score of 21 (20-22) and that of polycystic-liver-disease was 26% (nâ¯=â¯11). End-stage-renal-disease of unknown origin was 36.2% (nâ¯=â¯12). Dialysis before transplantation was performed in 54,8% (nâ¯=â¯23) of patients. The median TPA was 1138 (926-1510)â¯mm2, and sarcopenia was detected in 72% of patients (nâ¯=â¯31). No difference in patient or death-censored graft-survival between sarcopenic and non-sarcopenic groups at 1 year was reported. Also, no differences at 6-months' post-transplant-complication-free and infection-free-survival rates were found. CONCLUSION: In this cohort of patients, no differences were observed in patients, grafts, complications or infection-free survival between sarcopenic or no sarcopenic SLKT patients. Future multi-centre studies are needed to validate and extend the generalisability of these findings.
